Search for a trial

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

This study has been transitioned to CTIS with ID 2024-513759-34-00 check the CTIS register for the current data. Primary ObjectivesPhase 2The primary objectives of Phase 2 are:• To evaluate short- and long-term safety and tolerability of SNDX 5613…

A radical Chemoradiation schedule with hypofractionated radiotherapy plus capecitabine for esophageal cancer patients that are unfit for the standard chemoradiation; a phase II study

Objective of the study is to investigate if a mild sensitizing drug (oral capecitabine) combined with a high dose hypofractionated radiation regime to the esophageal region is feasible in this unfit patient group. If feasible, in a consecutive study…